NextSeq 500 paired end sequencing; RNA sequencing data from Myeloid Leukaemia of Down Syndrome (ML-DS)
RNA sequencing data from Myeloid Leukaemia of Down Syndrome (ML-DS)
Neonates with Transient Abnormal myelopoiesis (TAM) were (i) sourced within 3 months from birth (majority under 14 days of age), (ii) positive for a GATA1 variant by deep sequencing/conventional Sanger sequencing and (iii) evidence of subsequent clinical and/or GATA1 mutation resolution. ML-DS samples were allocated if ≥3 months from birth, positive for GATA1 variant (by criteria above), and ML-DS relapse if post treatment and GATA1 mutation positive. For sequential samples, “Progressive TAM” refers to samples taken over 3 months from birth where neonates still had a clinical diagnosis of TAM, irrespective of treatment status.  100 cells were sorted directly into lysis buffer containing RNAse inhibitor (Clontech).  cDNA synthesis was performed using SmartSeq-V4 Ultra low input RNA kit (Clontech).  The Nextera XT DNA sample preparation kit and Index Kit was used to generate Illumina libraries (Illumina UK).  Library size and quality were checked using the Agilent Bioanalyser (Agilent Technologies UK).